{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:03:56Z","timestamp":1783119836253,"version":"3.54.6"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>5q-associated spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) are two distinct neurological disorders leading to degeneration of lower motor neurons. The antisense oligonucleotides (ASOs) nusinersen and tofersen are novel disease-modifying agents for these diseases, respectively. In the context of ASO treatment, the cytological characteristics and composition of cerebrospinal fluid (CSF) have recently garnered particular interest. This report presents a case series of CSF cytology findings in two patients with SMA and ALS revealing comparable unspecified macrophage inclusions following treatment initiation with nusinersen and tofersen. Yet, the presence of these \u201casophages\u201d in the treatment course of two different ASOs is of unclear significance. While both treatments have been well tolerated, this phenomenon warrants attention, given the long-term nature of these treatments.<\/jats:p>","DOI":"10.1186\/s42466-023-00305-0","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:02:47Z","timestamp":1708560167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases"],"prefix":"10.1186","volume":"6","author":[{"given":"Maximilian","family":"Vidovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Menschikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Freigang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna Sophie","family":"Lapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"issue":"18","key":"305_CR1","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., Topaloglu, H., Tulinius, M., Montes, J., Glanzman, A. M., Bishop, K., Zhong, Z. J., Gheuens, S., Bennett, C. F., Schneider, E., & ENDEAR Study Group. (2017). Nusinersen versus Sham Control in infantile-onset spinal muscular atrophy. The New England Journal of Medicine, 377(18), 1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"305_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42466-021-00162-9","volume":"4","author":"S Jablonka","year":"2022","unstructured":"Jablonka, S., Hennlein, L., & Sendtner, M. (2022). Therapy development for spinal muscular atrophy: Perspectives for muscular dystrophies and neurodegenerative disorders. Neurological Research and Practice, 4(1), 2. https:\/\/doi.org\/10.1186\/s42466-021-00162-9.","journal-title":"Neurological Research and Practice"},{"issue":"2","key":"305_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., Maragakis, N. J., McDermott, C. J., Pestronk, A., Ravits, J., Salachas, F., Trudell, R., Van Damme, P., Zinman, L., Bennett, C. F., & Ferguson, T. A. (2020). Phase 1\u20132 trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. The New England Journal of Medicine, 383(2), 109\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa2003715.","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"305_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chi\u00f2, A., Van Damme, P., Ludolph, A. C., Glass, J. D., Andrews, J. A., Babu, S., Benatar, M., McDermott, C. J., Cochrane, T., Chary, S., Chew, S., Zhu, H., Wu, F., & Fradette, S. (2022). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 387(12), 1099\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa2204705.","journal-title":"New England Journal of Medicine"},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3389\/fneur.2019.00735","volume":"10","author":"S Gingele","year":"2019","unstructured":"Gingele, S., H\u00fcmmert, M. W., Alvermann, S., Jendretzky, K. F., B\u00f6nig, L., Brieskorn, M., Schwenkenbecher, P., S\u00fchs, K. W., M\u00fcschen, L. H., Osmanovic, A., Schreiber-Katz, O., Stangel, M., Petri, S., & Skripuletz, T. (2019). Routine cerebrospinal fluid cytology reveals unique inclusions in macrophages during treatment with Nusinersen. Frontiers in Neurology, 10, 735. https:\/\/doi.org\/10.3389\/fneur.2019.00735.","journal-title":"Frontiers in Neurology"},{"issue":"1","key":"305_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000518005","volume":"66","author":"KT Schafernak","year":"2022","unstructured":"Schafernak, K. T., Jacobsen, J. R., Hernandez, D., Kaye, R. D., & Perez, S. E. (2022). Cytochemical characterization of Cerebrospinal Fluid Macrophage inclusions in Pediatric patients receiving Intrathecal Nusinersen (SPINRAZA\u00ae) for spinal muscular atrophy. Acta Cytologica, 66(1), 79\u201384. https:\/\/doi.org\/10.1159\/000518005.","journal-title":"Acta Cytologica"},{"key":"305_CR7","doi-asserted-by":"publisher","unstructured":"Machacek, M. E., Gogakos, T., Fletcher, M. C., Lunderville, K. A., Swoboda, K. J., & Sohani, A. R. (2021). Unusual inclusions in cerebrospinal fluid macrophages of spinal muscular atrophy patients treated with nusinersen. International Journal of Laboratory Hematology, 43(3). https:\/\/doi.org\/10.1111\/ijlh.13392.","DOI":"10.1111\/ijlh.13392"},{"key":"305_CR8","doi-asserted-by":"publisher","unstructured":"Sparasci, D., Castelli, C., Staedler, C., Gobbi, C., & Ripellino, P. (2023). Inclusions in macrophages of the cerebrospinal fluid during treatment with Tofersen. Muscle & Nerve, 67(2). https:\/\/doi.org\/10.1002\/mus.27763.","DOI":"10.1002\/mus.27763"},{"key":"305_CR9","doi-asserted-by":"publisher","unstructured":"Freigang, M., Steinacker, P., Wurster, C. D., Schreiber-Katz, O., Osmanovic, A., Petri, S., Koch, J. C., Rost\u00e1sy, K., Falkenburger, B., Ludolph, A. C., Otto, M., Hermann, A., & G\u00fcnther, R. (2021). Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 16(1), 330. https:\/\/doi.org\/10.1186\/s13023-021-01961-8.","DOI":"10.1186\/s13023-021-01961-8"},{"issue":"3","key":"305_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/brainsci11030296","volume":"11","author":"LH M\u00fcschen","year":"2021","unstructured":"M\u00fcschen, L. H., Osmanovic, A., Binz, C., Jendretzky, K. F., Ranxha, G., Bronzlik, P., Abu-Fares, O., Wiehler, F., M\u00f6hn, N., H\u00fcmmert, M. W., Gingele, S., G\u00f6tz, F., Stangel, M., Skripuletz, T., Schreiber-Katz, O., & Petri, S. (2021). Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-Spinal muscular atrophy patients. Brain Sciences, 11(3), 296. https:\/\/doi.org\/10.3390\/brainsci11030296.","journal-title":"Brain Sciences"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-023-00305-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-023-00305-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-023-00305-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:03:30Z","timestamp":1708560210000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-023-00305-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/s42466-023-00305-0","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MF has received a speaker honorarium and non-financial support from Biogen outside the submitted work. HSL has received advisory fees from Biogen outside the submitted work. RG has received non-financial support, travel expenses and honoraria as a speaker\/adboard member as well as research support from Biogen and honoraria as an adboard member from Roche outside the submitted work. The other authors have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}